Mary Long
Family · Low Moor, VANPI 1659939387
Payments from drug & device makers
Across 267 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$451
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$443
- Johnson & Johnson$421
- Novo Nordisk$251
- Alkermes, Inc.$234
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$2,50039%
- Travel & lodging$771%
- Food & beverage$3,86860%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $3,404 |
| Otsuka America Pharmaceutical, Inc. | 24 | $451 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $443 |
| Johnson & Johnson | 27 | $421 |
| Novo Nordisk | 16 | $251 |
| Alkermes, Inc. | 16 | $234 |
| Indivior Inc. | 9 | $185 |
| Avanir Pharmaceuticals, Inc. | 7 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $111 |
| Neurocrine Biosciences, Inc. | 6 | $107 |
| E.r. Squibb & Sons, L.L.C. | 4 | $92 |
| Boehringer Ingelheim | 5 | $90 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Amarin Pharma, Inc. | 4 | $68 |
| GSK | 4 | $60 |
| Pfizer | 4 | $58 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Lilly USA, LLC | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Gilead | 2 | $31 |
| AstraZeneca | 2 | $29 |
| Lundbeck LLC | 1 | $28 |
| Merck | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Biogen | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$2,500
How this compares
$6,491 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $118,797 |
| RexultiBrexpiprazole | 24 | $34,378 |
| LatudaLurasidone Hcl | 16 | $29,232 |
| VraylarCariprazine Hcl | 17 | $23,714 |
| TrintellixVortioxetine Hydrobromide | 19 | $8,732 |
| Bupropion XlBupropion Hcl | 91 | $2,186 |
| Lurasidone Hcl | 39 | $2,136 |
| Aripiprazole | 71 | $1,767 |
| Fluvoxamine Maleate | 12 | $1,287 |
| Duloxetine Hcl | 85 | $1,200 |
| Buspirone Hcl | 118 | $1,103 |
| Trazodone Hcl | 88 | $759 |
| Methylphenidate Hcl | 25 | $707 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $704 |
| Fluoxetine Hcl | 66 | $654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $107 | $118,79714 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $451 | $34,37824 claims |
| AbbVieVraylar | $3,404 | $23,71417 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $111 | $8,73219 claims |
| Lilly USA, LLCOlanzapine | $46 | $53443 claims |
| Almatica Pharma LLCSertraline Hcl | $12 | $45246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Low Moor
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.